Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance

Theranostics

Volumn 4, Issue 3, 2014, Pages 267-279

  LeBeau, Aaron M ^a   Sevillano, Natalia ^b   King, Mandy L ^c   Duriseti, Sai ^b   Murphy, Stephanie T ^a   Craik, Charles S ^b   Murphy, Laura L ^c   VanBrocklin, Henry F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistant breast cancer; Human antibody; Phage display; Single photon emission computed tomography; Tamoxifen resistance; Urokinase plasminogen activator receptor

Indexed keywords

DRUG-RESISTANT BREAST CANCER; HUMAN ANTIBODY; PHAGE DISPLAY.; SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY; TAMOXIFEN RESISTANCE; UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; MCF-7 CELLS; MICE; MULTIMODAL IMAGING; OPTICAL IMAGING; PACLITAXEL; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TAMOXIFEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893566219     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7323     Document Type: Article

References (27)

1. Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer. 2012; 106: 6-13. doi:10.1038/bjc.2011.516 bjc2011516 [pii].
2. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003; 9: 5078-84.
3. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005; 23: 2469-76. doi:JCO.2005.01.172 [pii] 10.1200/JCO.2005.01.172.
4. Boyle DP, Mullan P, Salto-Tellez M. Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: a comprehensive review of biomarkers related to therapeutic interventions. Biochim Biophys Acta. 2013; 1835: 230-42. doi:10.1016/j.bbcan.2013.01.004 S0304-419X(13)00005-X [pii].
5. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009; 27: 542-9. doi:10.1200/JCO.2008.17.1462 JCO.2008.17.1462 [pii].
6. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci. 2005; 1059: 70-5. doi:1059/1/70 [pii] 10.1196/annals.1339.026.
7. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1: 1-11. doi:10.1634/theoncologist.2011-S1-01 16/suppl_1/1 [pii].
8. Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012; 23 Suppl 6: vi46-51. doi:mds195 [pii] 10.1093/annonc/mds195.
9. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53: 615-27. doi:10.1146/annurev.med.53.082901.103929 53/1/615 [pii].
10. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29: 4741-51. doi:10.1038/onc.2010.215 onc2010215 [pii].
11. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003; 22: 205-22.
12. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev. 2007; 33: 521-7. doi:S0305-7372(07)00076-X [pii] 10.1016/j.ctrv.2007.06.003.
13. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, et al. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013; 73: 2070-81. doi:10.1158/0008-5472.CAN-12-3526 0008-5472.CAN-12-3526 [pii].
14. Bianchi E, Cohen RL, Thor AT, Todd RF, 3rd, Mizukami IF, Lawrence DA, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 1994; 54: 861-6.
15. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993; 53: 1911-5.
16. Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer. 1996; 66: 441-52. doi:10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W [pii] 10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W.
17. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res. 1994; 54: 5445-54.
18. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, et al. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 2004; 64: 4563-8. doi:10.1158/0008-5472.CAN-03-3848 64/13/4563 [pii].
19. Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem. 2010; 285: 26878-88. doi:M109.077677 [pii] 10.1074/jbc. M109.077677.
20. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate. 2012; 72: 638-48. doi:10.1002/pros.21467.
21. He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, et al. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med. 2010; 51: 427-32. doi:10.2967/jnumed.109.069492 jnumed.109.069492 [pii].
22. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013; 110: 93-8. doi:10.1073/pnas.1218694110 1218694110 [pii].
23. Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, et al. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012; 53: 138-45. doi:10.2967/jnumed.110.083386 53/1/138 [pii].
24. Sliutz G, Eder H, Koelbl H, Tempfer C, Auerbach L, Schneeberger C, et al. Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. Breast Cancer Res Treat. 1996; 40: 257-63.
25. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006; 118: 290-301. doi:10.1002/ijc.21355.
26. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3: 932-43. doi:10.1038/nrm977 nrm977 [pii].
27. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009; 284: 22825-33. doi:M109.023960 [pii] 10.1074/jbc. M109.023960.